Literature DB >> 8661395

Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.

J A McKeating1, Y J Zhang, C Arnold, R Frederiksson, E M Fenyö, P Balfe.   

Abstract

We constructed a number of HXB2 viruses chimeric for the gp 120 glycoprotein derived from a number of viable molecular clones obtained from a primary isolate. Comparative biological characterization of the parental primary viruses with the gp 120.HXB2 chimeras demonstrated identical patterns of cell tropism and cytopathicity. Furthermore, both parental and chimeric viruses were insensitive to neutralization by sCD4 and a panel of conformation-dependent monoclonal antibodies, demonstrating that transfer of the gp 120 protein alone was sufficient to confer a "neutralization-resistant" phenotype to the T-cell-adapted clone HXB2. We assessed the contribution of gp 120 epitopes to the neutralizing immune response by comparing the sensitivity of these viruses to neutralization by a panel of sera from HIV-infected individuals. Seven of eleven sera tested were able to neutralize HXB2 and two or more of the chimeric viruses; in contrast, only one serum neutralized more than one of the parental primary virus clones. The association of gp 120-gp41 envelope at the surface of infected PBMC cultures was measured in the presence or absence of soluble CD4. No differences in CD4-induced gp 120 dissociation were seen between the chimeric and parental virus-infected cultures. Since gp 120 conformation appeared the same between primary and chimeric viruses, we suggest that the ability of human sera to neutralize the chimeric viruses may be mediated by epitopes within gp41.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8661395     DOI: 10.1006/viro.1996.0332

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.

Authors:  A L Hammond; J Lewis; J May; J Albert; P Balfe; J A McKeating
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

2.  Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120.

Authors:  Ralph Pantophlet; Erica Ollmann Saphire; Pascal Poignard; Paul W H I Parren; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

3.  Functional characterization of intracellular and secreted forms of a truncated hepatitis C virus E2 glycoprotein.

Authors:  M Flint; J Dubuisson; C Maidens; R Harrop; G R Guile; P Borrow; J A McKeating
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

4.  Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex.

Authors:  T R Fouts; J M Binley; A Trkola; J E Robinson; J P Moore
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection.

Authors:  Marlén M I Aasa-Chapman; Sophie Holuigue; Keith Aubin; Mailee Wong; Nicola A Jones; David Cornforth; Pierre Pellegrino; Philippa Newton; Ian Williams; Persephone Borrow; Aine McKnight
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

6.  In vivo emergence of HIV-1 highly sensitive to neutralizing antibodies.

Authors:  Marlén M I Aasa-Chapman; Kelly M Cheney; Stéphane Hué; Anna Forsman; Stephen O'Farrell; Pierre Pellegrino; Ian Williams; Áine McKnight
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

7.  Generation of a family-specific phage library of llama single chain antibody fragments that neutralize HIV-1.

Authors:  Willie W L Koh; Soren Steffensen; Maria Gonzalez-Pajuelo; Bart Hoorelbeke; Andrea Gorlani; Agnieszka Szynol; Anna Forsman; Marlén M I Aasa-Chapman; Hans de Haard; Theo Verrips; Robin A Weiss
Journal:  J Biol Chem       Date:  2010-04-16       Impact factor: 5.157

8.  The human immunodeficiency virus type 1 envelope spike of primary viruses can suppress antibody access to variable regions.

Authors:  Ralph Pantophlet; Meng Wang; Rowena O Aguilar-Sino; Dennis R Burton
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

9.  Development of a neutralizing antibody response during acute primary human immunodeficiency virus type 1 infection and the emergence of antigenic variants.

Authors:  J Lewis; P Balfe; C Arnold; S Kaye; R S Tedder; J A McKeating
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.